Oxidative Stress in Women Treated with Atosiban for Impending Preterm Birth

Preterm birth is defined as delivery before 37 completed weeks of pregnancy, and it is the leading cause of neonatal morbidity and mortality. Oxidative stress is recognized as an important factor in the pathogenesis of premature labor. We conducted this analysis to investigate the safety of administ...

Full description

Saved in:
Bibliographic Details
Published in:Oxidative medicine and cellular longevity 2018-01, Vol.2018 (2018), p.1-8
Main Authors: Banach, Maciej, Horzelski, Wojciech, Oszukowski, Przemysław, Suliburska, Joanna, Kocyłowski, Rafał, Gaj, Zuzanna, Grzesiak, Mariusz, von Kaisenberg, C.
Format: Article
Language:English
Subjects:
Analysis
Antioxidants
Biomarkers
Blood proteins
Clinical Study
Drug dosages
Endocrinology
Enzyme-linked immunosorbent assay
Ethylenediaminetetraacetic acid
Gynecology
Hospitals
Infants (Premature)
Mortality
Obstetrics
Oxidative stress
Poland
Pregnancy
Pregnancy complications
Pregnant women
Premature birth
Proteins
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Preterm birth is defined as delivery before 37 completed weeks of pregnancy, and it is the leading cause of neonatal morbidity and mortality. Oxidative stress is recognized as an important factor in the pathogenesis of premature labor. We conducted this analysis to investigate the safety of administration of the tocolytic drug Atosiban—a reversible, competitive antagonist of the oxytocin receptor in the treatment of preterm birth and its impact on the level of oxidative stress in pregnant women after 48 hours of tocolytic treatment. This prospective study was conducted between March 2016 and August 2017 at the Obstetric Clinic of the Polish Mother’s Memorial Hospital Research Institute. Total oxidant status (TOS), total antioxidant status (TAS), and oxidative stress index (OSI) values as well as 3-nitrotyrosine, carbonyl, and thiol group levels were measured using an ELISA test in serum and plasma of 56 pregnant women before and after 48 hours of continuous administration of Atosiban. We found that TAS levels decreased almost twice after the 48-hour drug administration (0.936 ± 0.360 mmol/L vs. 0.582 ± 0.305 mmol/L, P
ISSN:1942-0900
1942-0994
DOI:10.1155/2018/3919106